Contract Manufacturing, In-Vivo and Protein - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Contract Manufacturing

In-Vivo

Protein

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

JANUARY 14, 2024

Moreover, the exuberant development of biologics has revolutionized the treatment of a range of therapeutic conditions, which has further contributed to the exponential growth in the current demand for biologic therapies developed by biologics manufacturing companies.

Contract Manufacturing

Contract Manufacturing Protein Manufacturing Production

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval

FDA Approval Manufacturing In-Vivo Trials

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Biologics – The Next Step in Revolutionary Medication

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

Webinars

Stay Connected